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Background: Drug-eluting stents (DES) are routinely used in complex patients but their impact on clinical outcomes has not been well described. 
We aim to assess the efficacy and safety of 2nd-generation (everolimus-eluting) compared to 1st-generation (sirolimus- and paclitaxel-eluting) DES 
in a selected higher-risk complex population.
methods: The study included 5693 consecutive patients with ≥1 predefined complex clinical and angiographic characteristic(s) treated with any 
DES. Using propensity-score (PS) matching, clinical outcomes of 1076 patients treated with 2nd-generation DES were compared with outcomes of a 
matched population treated with 1st-generation DES.
results: After PS matching, baseline characteristics were similar. At 1-year follow-up, major adverse cardiac events (MACE) was 8.8% with 2nd-
generation DES vs 11.0% with 1st-generation DES (p=0.09). There were no significant differences in the rates of death (3.2 vs. 4.0%, p=0.30), 
Q-wave myocardial infarction (0.1 vs. 0.3%, p=0.63), target vessel revascularization (5.9 vs. 7.3%, p=0.17) or target lesion revascularization (4.4 vs. 
5.0%, p=0.50). Definite stent thrombosis (ST) was less frequent with 2nd-generation DES than 1st-generation DES (0.1 vs. 0.8%, p=0.011). Figure 
shows hazard ratios for 1-year outcomes.
conclusions: In this PS-matched complex population undergoing PCI, use of 2nd-generation DES proved efficacious and safe, with reduction of ST 
and a trend toward reduction of MACE compared to 1st-generation DES.
 
